BCX 7353

Drug Profile

BCX 7353

Alternative Names: BCX7353

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioCryst Pharmaceuticals
  • Class Skin disorder therapies; Small molecules
  • Mechanism of Action Bradykinin inhibitors; Kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hereditary angioedema

Most Recent Events

  • 05 Sep 2017 Final efficacy and adverse event data from the phase II APeX-1 trial in Hereditary angioedema attacks released by BioCryst Pharmaceuticals
  • 05 Sep 2017 BioCryst completes the phase II APeX-1 trial in Hereditary angioedema in Australia, Austria, Canada, Denmark, Germany, Hungary, Italy, Macedonia, Spain, Switzerland and the United Kingdom
  • 05 Sep 2017 BioCryst plans a phase III trial for Hereditary angioedema attacks in the first quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top